Why the study?
Emergence of vaccine-derived poliovirus and limitations of existing vaccines warranted the development of more genetically stable OPV strains, particularly for OPV2.
A novel codon-deoptimized oral poliovirus vaccine candidate (nOPV2-CD) demonstrates comparable immunogenicity and superior genetic stability compared to traditional Sabin OPV2 in preclinical models.
No takes yet. Share an insight, caveat, or question.
Persistent VDPV outbreaks despite OPV2 cessation warrant caution on OPV use; leaves open safer vaccine strategies for eradication.
Konopka‐Anstadt et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: